BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Vertex Pharmaceuticals (MA) (VRTX) Gears Up Sales Force for CF Drug Launch, 150 Jobs Available Now, 500 by 2015


9/16/2011 8:12:42 AM

Biotech firm Vertex, fresh off the introduction of Incivek for hepatitis C, is busying itself with launch preparations once again. The firm said it's hiring across the company to support the anticipated debut of cystic fibrosis (CF) drug VX-770.

Submissions to regulatory authorities in the US and Europe are timed for next month. And, much like it did last year around this time, Vertex is bulking up globally by hiring for 150 jobs, and a total of 500 by 2015, much of that in sales and marketing.

“We're going to repeat it all heading into next year with the anticipated approval of VX-770,” said spokesperson Dawn Kalmar. “Obviously, it's a much smaller market [than Incivek's]—there are about 4% of people with CF who we believe VX-770 is most appropriate for. It will be a small commercial force but one we're ramping up.”

CF, an inherited chronic disease affecting the lungs and digestive system, strikes about 30,000 children and adults in the US and 70,000 worldwide, according to the Cystic Fibrosis Foundation.

Across the pond, Vertex's European affiliate is growing its commercial organization, too, she said.

To support its science culture, Vertex said it also introduced two new programs to help scientists learn about and stay connected to the commercial part of the company: a ride-along program enabling researchers to shadow sales reps for a day and another that gives scientists a seat on hiring committees for certain commercial employees.

Both programs are meant to foster collaboration across the organization, especially among groups that otherwise may not talk to or even see one another.

“When you think about this from the researcher's perspective,” said Kalmar, “they've poured years, decades of their careers into developing one new medicine, and then handing it over to someone to represent their scientific work in the commercial world to customers and, ultimately, to physicians and patients who will be using these medicines. It's a big responsibility that we feel our sales force is carrying with them.”



Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES